Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury

Frontiers in Physiology

Volumn 4 JUN, Issue , 2013, Pages

  Egom, Emmanuel E ^a,b   Mamas, Mamas A ^b,c   Chacko, Sanoj ^d   Stringer, Sally E ^b   Charlton Menys, Valentine ^b   El Omar, Magdi ^c   Chirico, Debora ^c   Clarke, Bernard ^c   Neyses, Ludwig ^b,c   Cruickshank, Kennedy J ^b   Lei, Ming ^b   Fath Ordoubadi, Farzin ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Ischaemia; Sphingolipids; Sphingosine 1 phosphate

Indexed keywords

C REACTIVE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; SPHINGANINE; SPHINGOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; TROPONIN T;

ADULT; AGED; ARTICLE; BALLOON OCCLUSION; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY SINUS; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; FEMORAL VEIN; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID BLOOD LEVEL; MALE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; THORAX PAIN;

EID: 84884575993     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00130     Document Type: Article

References (33)

1. Alewijnse, A. E., and Peters, S. L. M. (2008). Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur. J. Pharmacol. 585, 292-302. doi: 10.1016/j.ejphar.2008.02.089
2. Bonaca, M., Scirica, B., Sabatine, M., Dalby, A., Spinar, J., Murphy, S. A., et al. (2010). Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin i. J. Am. Coll. Cardiol. 55, 2118-2124. doi: 10.1016/j.jacc.2010.01.044
3. Budde, K., Schutz, M., Glander, P., Peters, H., Waiser, J., Liefeldt, L., et al. (2006). Fty720 (fingolimod) in renal transplantation. Clin. Transplant. 20(Suppl 17), 17-24. doi: 10.1111/j.1399-0012.2006.00596.x
4. Buffon, A., Santini, S. A., Ramazzotti, V., Rigattieri, S., Liuzzo, G., Biasucci, L. M., et al. (2000). Large, sustained cardiac lipid peroxidation and reduced antioxidant capacity in the coronary circulation after brief episodes of myocardial ischemia. J. Am. Coll. Cardiol. 35, 633-639.
5. Caligan, T. B., Peters, K., Ou, J., Wang, E., Saba, J., and Merrill, A. H. (2000). A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples. Anal. Biochem. 281, 36-44. doi: 10.1006/abio.2000.4555
6. Colli, A., Josa, M., Pomar, J. L., Mestres, C. A., and Gherli, T. (2007). Heart fatty acid binding protein in the diagnosis of myocardial infarction: where do we stand today? Cardiology 108, 4-10. doi: 10.1159/000095594
7. Deutschman, D. H., Carstens, J. S., Klepper, R. L., Smith, W. S., Page, M. T., Young, T. R., et al. (2003). Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am. Heart J. 146, 62-68. doi: 10.1016/S0002-8703(03)00118-2
8. Egom, E. E., Ke, Y., Musa, H., Mohamed, T. M., Wang, T., Cartwright, E., et al. (2010a). Fty720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of pak1/akt signaling. J. Mol. Cell. Cardiol. 48, 406-414. doi: 10.1016/j.yjmcc.2009.10.009
9. Egom, E. E., Ke, Y., Solaro, R. J., and Lei, M. (2010b). Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling. Prog. Biophys. Mol. Biol. 103, 142-147. doi: 10.1016/j.pbiomolbio.2010.01.001
10. Ehara, S., Naruko, T., Shirai, N., Itoh, A., Hai, E., Sugama, Y., et al. (2008). Small coronary calcium deposits and elevated plasma levels of oxidized low density lipoprotein are characteristic of acute myocardial infarction. J. Atheroscler. Thromb. 15, 75-81.
11. Govindan, S., McElligott, A., Muthusamy, S., Nair, N., Barefield, D., Martin, J. L., et al. (2012). Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J. Mol. Cell. Cardiol. 52, 154-164. doi: 10.1016/j.yjmcc.2011.09.011
12. Guo, J., MacDonell, K. L., and Giles, W. R. (1999). Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch. 438, 642-648.
13. Helleskov Madsen, L., Ladefoged, S., Hildebrandt, P., and Atar, D. (2008). Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. Acute Card. Care 10, 173-180. doi: 10.1080/17482940802100279
14. Holvoet, P., Macy, E., Landeloos, M., Jones, D., Nancy, J. S., Van de Werf, F., et al. (2006). Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized ldl. Clin. Chem. 52, 760-764. doi: 10.1373/clinchem.2005.064337
15. Holvoet, P., Vanhaecke, J., Janssens, S., Van de Werf, F., and Collen, D. (1998). Oxidized ldl and malondialdehyde-modified ldl in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98, 1487-1494.
16. Jin, Z.-Q., Zhou, H.-Z., Zhu, P., Honbo, N., Mochly-Rosen, D., Messing, R. O., et al. (2002). Cardioprotection mediated by sphingosine-1-phosphate and ganglioside gm-1 in wild-type and pkcepsilon knockout mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 282, H1970-H1977. doi: 10.1152/ajpheart.01029.2001
17. Karliner, J. S. (2009). Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J. Cardiovasc. Pharmacol. 53, 189-197. doi: 10.1097/FJC.0b013e3181926706
18. Karliner, J. S., Honbo, N., Summers, K., Gray, M. O., and Goetzl, E. J. (2001). The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 33, 1713-1717. doi: 10.1006/jmcc.2001.1429
19. Keller, T., Zeller, T., Peetz, D., Tzikas, S., Roth, A., Czyz, E., et al. (2009). Sensitive troponin i assay in early diagnosis of acute myocardial infarction. N. Engl. J. Med. 361, 868-877. doi: 10.1056/NEJMoa0903515
20. Kelly, R. F., Lamont, K. T., Somers, S., Hacking, D., Lacerda, L., Thomas, P., et al. (2010). Ethanolamine is a novel stat-3 dependent cardioprotective agent. Basic Res. Cardiol. 105, 763-770. doi: 10.1007/s00395-010-0125-0
21. Keul, P., Lucke, S., von Wnuck Lipinski, K., Bode, C., Graler, M., Heusch, G., et al. (2011). Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ. Res. 108, 314-323. doi: 10.1161/CIRCRESAHA.110.235028
22. Keul, P., Tolle, M., Lucke, S., von Wnuck Lipinski, K., Heusch, G., Schuchardt, M., et al. (2007). The sphingosine-1-phosphate analogue fty720 reduces atherosclerosis in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27, 607-613. doi: 10.1161/01.ATV.0000254679.42583.88
23. Knapp, M., Baranowski, M., Czarnowski, D., Lisowska, A., Zabielski, P., Górski, J., et al. (2009). Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med. Sci. Monit. 15, 490-493.
24. Koyrakh, L., Roman, M. I., Brinkmann, V., and Wickman, K. (2005). The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am. J. Transplant 5, 529-536. doi: 10.1111/j.1600-6143.2005.00754.x
25. Maceyka, M., Milstien, S., and Spiegel, S. (2007). Shooting the messenger: Oxidative stress regulates sphingosine-1-phosphate. Circ. Res. 100, 7-9. doi: 10.1161/01.RES.0000255895.19868.a3
26. Nikolic-Heitzler, V., Rabuzin, F., Tatzber, F., Vrkic, N., Bulj, N., Borovic, S., et al. (2006). Persistent oxidative stress after myocardial infarction treated by percutaneous coronary intervention. Tohoku J. Exp. Med. 210, 247-255.
27. Sattler, K. J., Elbasan, S., Keul, P., Elter-Schulz, M., Bode, C., Graler, M. H., et al. (2010). Sphingosine 1-phosphate levels in plasma and hdl are altered in coronary artery disease. Basic Res. Cardiol. 105, 821-832. doi: 10.1007/s00395-010-0112-5
28. Theilmeier, G., Schmidt, C., Herrmann, J., Keul, P., Schafers, M., Herrgott, I., et al. (2006). High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the s1p3 lysophospholipid receptor. Circulation 114, 1403-1409. doi: 10.1161/CIRCULATIONAHA.105.607135
29. Thielmann, M., Dorge, H., Martin, C., Belosjorow, S., Schwanke, U., van de Sand, A., et al. (2002). Myocardial dysfunction with coronary microembolization: Signal transduction through a sequence of nitric oxide, tumor necrosis factor-{alpha}, and sphingosine. Circ. Res. 90, 807-813.
30. Vessey, D. A., Li, L., Honbo, N., and Karliner, J. S. (2009). Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning. Am. J. Physiol. Heart Circ. Physiol. 297, H1429-H1435. doi: 10.1152/ajpheart.00358.2009
31. Yatomi, Y., Igarashi, Y., Yang, L., Hisano, N., Qi, R., Asazuma, N., et al. (1997). Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J. Biochem. 121, 969-973.
32. Yatomi, Y., Ruan, F., Hakomori, S., and Igarashi, Y. (1995). Sphingosine-1-phosphate: A platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood 86, 193-202.
33. Zhang, D. X., Fryer, R. M., Hsu, A. K., Zou, A. P., Gross, G. J., Campbell, W. B., et al. (2001). Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res. Cardiol. 96, 267-274.